Effector Therapeutics Inc (EFTR) — Cash Flow Quality Index
Effector Therapeutics Inc (EFTR) has a Cash Flow Quality Index of -2.12x as of March 2022. Operating cash flow of $-6.50 Million is below net income of $3.07 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how well can Effector Therapeutics Inc service its debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Effector Therapeutics Inc Cash Flow Quality Index (2020–2021)
Historical Cash Flow Quality Index for Effector Therapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Effector Therapeutics Inc cash flow conversion.
Annual Cash Flow Quality Index for Effector Therapeutics Inc (2020–2021)
Year-by-year earnings quality comparison for Effector Therapeutics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | -1.58x | $-24.89 Million | $15.80 Million | ▼ -261.8% |
| 2020 | 0.97x | $13.84 Million | $14.21 Million | — |